Copy Link Print Information

BMS-309403

29 Cited Publications
Customer Review

Based on 29 publication(s) in Google Scholar

BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.

For research use only. We do not sell to patients.

  • Purity: 99.91%
  • CAS No.: 300657-03-8
  • Formula: C31H26N2O3
  • Molecular Weight:474.55
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • BMS-309403 Chemical Structure
    BMS-309403 Chemical Structure
  • Experimental Validation Results for BMS-309403
  • Experimental Validation Results for BMS-309403
  • Experimental Validation Results for BMS-309403
  • Experimental Validation Results for BMS-309403
  • Experimental Validation Results for BMS-309403
  • Experimental Validation Results for BMS-309403
CAS No.: 300657-03-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of BMS-309403:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) BMS-309403

More
Customer Validation & Images
Cell Imaging/StainingIn Vivo Efficacy StudyHistological Imaging/StainingWB
  • In Vivo Efficacy Study
  • Cell Imaging/Staining
  • Cell Imaging/Staining
  • Histological Imaging/Staining
  • Histological Imaging/Staining
  • WB
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • BMS-309403 Chemical Structure
    BMS-309403 Chemical Structure
    1/16
  • 1/16

    BMS-309403 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Oct 28:575:216403. [Abstract]

    Customer Validation
     STAM mice were treated with small-molecule inhibitors targeting LPL (Orlistat, S+O), FABP4 (BMS309403 (15 mg/kg, ip, twice a week), S+B), or CPT1 (Etomoxir, S+E). Tumor burden was reduced in all inhibitor-treated groups compared to the STAM control group.

  • 1/16

    BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

    Customer Validation
     The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. Tube formation assay and quantification of HUVECs cultured with vehicle (C), rhFABP4 (P), rhFABP4 + BMS309403 (20 μmol/L, 1h) (PB). Scale bar: 100 µm.

  • 1/16

    BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

    Customer Validation
     The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. Tube formation assay and quantification of HUVECs cultured with vehicle (C), M1-polarized macrophage supernatant (S), or M1-polarized macrophage supernatant+BMS309403 (20 μmol/L, 1h) (SB) (n = 3 per group). Scale bar: 100 µm.

  • 1/16

    BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

    Customer Validation
     Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 (5 mg/kg, ip, twice a week) or anagliptin for 4 weeks after AIA modeling (n = 10 per group). Scale bar: 12.5 µm and 100 µm.

  • 1/16

    BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

    Customer Validation
     Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 (5 mg/kg, ip, twice a week) or anagliptin for 8 weeks after AIA modeling (n = 10 per group). Scale bar: 12.5 µm and 100 µm.

  • 1/16

    BMS-309403 purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2019 Oct 1;9(10):2140-2155. [Abstract]

    Customer Validation
     FABP4 expression is up-regulated in the metastatic tumor sites. BALB/C nude mice are intrahepatic inoculation of 5 × 106 HepG2 cells followed by intraperitoneally injection with PBS or 25-HC (10 mg/kg) or 25-HC with BMS-309403 (45 mg/kg). At the end of the experiment, mice are sacrificed, the tumor tissues in the livers of the mice without metastasis, with abdominal metastasis and the metastatic tumor sites are extracted. The mRNA and protein expression of FABP4 is assessed by RT-qPCR

  • BMS-309403